D&O Ongoing Disclosure – Warren Bell

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant lnterests
Secfions 297(2) and
298(2), Financial Ma*ets
Conduct
Act 2013
To NZX Limited; and
Name of listed issuer:
Date
this disclosure made:
Date
of
last
disclosure:
Director or senior manaqer
givinq
disclosure
Full name(s):
Name of listed issuer:
Name of related body corporate
(if
applicable):
Position held in listed issuer:
Summary of acquisition or disposal of relevant interest
(excluding
specified
derivatlves)
Class of affected
quoted
financial
products:
Nature ofthe affected
relevant interest(s):
For that
relevant
interest.
Number held in
class before acquisition or disposal:
Number held in
class after acquisition
or disposal:
Current
registered
holde(s):
Registered holder(s)
once
transfers are registered:
Summary of acquisition or disposal
of
specified
derivatives relevant interest
(if
applicable)
Type
of affected derivative:
Class
of underlvinq financial
Parties
to the derivative:
theor senior manager is
not
a
party
to the derivative, the
nature
of the
relevant
interest in the derivative:
Healthcare Limited
14 Auqust 2019
21 December2018
Wanen
James
Bell
Ryman
Healthcare
Limited
Director
1 3
Auoust 201
9
On market sale
N/A
$47 .279.54
(beino
$13,50844 Der
share)
3,500
Ordinary
shares
(NZX
code:
RYM)
Registered holder and beneficial owner
5,000
1,500
Warren James Bell
Warren
James
Bell
Details of affected derivative-
The notional value of the derivative
(if
any)
or the
notional amount of
underlying
financial
oroducts
(if
anv):
A
statement as to
whether the derivative is cash settled or
physically
settled:
Maturity date of the derivative
(if
any):
Expiry date of the derivative(if anv):
The
price
specified in the terms of the derivative
(if
any):
Any
other
details needed to understand
how
the amount
of the consideration
payable
under the derivative or
the value
of
the
derivative
is affected
by
the value of
the
underlying
financial
products:
For
that
derivative,-
Details of transactions
giving
rise to acquisltion or disposal
The
consideration, expressed
in New Zealand
dollars,
paid
or received for the
acquisition
or disposal.
lf
the consideration
was
not
in cash and cannot be
readily
by
converted into a
of financial
products
to which the transaction
related:
NZX

lf
the
issuer has a financial
products
trading
policy
that
prohibits
directors
or
senior
managers from
trading during any
period
without witten clearance
(a
closed
peiod)
For
that
relevant interest,-
class:
registered holcler(s):
shares
(NZX
code:
Kerr & Warren
James
Bell
Custodian for
the
Ryman
Healthcare
Employee Share Scheme
(held
prior
written
clearance was
provided
to allow
the acquisition
or disposal to
Date
of
the
prior
written clearance
(if
any):
Summary
of
other
relevsnt
interests
aftet acquisition
or disposal:
The
notional
value
of the derivative
(if
any)
or
the notional amount
of underlying financial
products
(if
any):
A
statement as to whether the
derivative
is
cash settled or
physically
settled:
Maturity date
of
the derivative
(if
any):
Expiry
date of the derivative
(if
any):
The
price's
specified terms
(if
any):
Any other details needed to
understand how the amount of the consideration
payable
under the derivative or the value
of the
derivative is
affected by the value of the
underlvinq
financial
Droducts:
For
that derivative
relevant interest,-
Parties to the
derivative:
lf
the director or senior manager is not a
party
to the
derivative,
the
nature
of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge
and belief, the
information
contained in
this
disclosure
is correct
and that
I
am duly authorised to make this disclosure
by all
persons
for whom it
is made.
Signature of
director
or officer;
14 August 2019
Signature
of
person
authorised
to
sign on behalf of director or officer:
Date of signature:
Name
and title of authorised
person:
Notes
Use this
form
to disclose all the acquisitions
and
disposals by a director
or senior
manager of
a
listed issuer,
or of a
related
body corporate, or
in
specified derivatives. The
disclosure must be made within-
(a)
20 working days
after the
first
acquisition or disposal disclosed
in this
notice if
the
acquisitions
or disposals are of a
kind referred to
in section 297(2Xa) of the
Financial
Markets
Conduct Act 2013; or

(b)
in
any
other
case,
5 trading
days
afier
the
first acquisition
or disposal
disclosed
in this
notice.